Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Background Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-ce...
Main Authors: | Patricia Pérez-Galán, Javier Melchor, Marcos Garcia-Lacarte, Sara C. Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco J. Novo, Juan Garcia Valero, Jose A. Martinez-Climent, Sergio Roa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/2/e006113.full |
Similar Items
-
The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
by: Marcos Garcia-Lacarte, et al.
Published: (2021-09-01) -
Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
by: Meng-Ke Liu, et al.
Published: (2022-10-01) -
Clinical features and therapy of double-hit and double-expressor lymphomas
by: E A Baryakh, et al.
Published: (2016-12-01) -
Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
by: Mohammad Barouqa, et al.
Published: (2022-08-01) -
Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma
by: Camila Peña, et al.
Published: (2020-04-01)